Scan-guided radiation for high-risk prostate cancer, with or without pelvis treatment

Trial details

Who runs it

AHS Cancer Control Alberta

Trial code

NCT07291557

Record updated

4 November 2026

Original description

In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy. PSMA imaging will be used to visualize prostate cancer prior to starting the trial.Read full original descriptionShow less

PSMA-PET Directed Radiation Therapy in High and Very High-Risk Prostate Cancer

In this study, prostate cancer patients whose cancer has not spread to the lymph nodes will receive radiation therapy targeted to the prostate and nearby tissues with or without whole pelvis radiation therapy. PSMA imaging will be used to visualize prostate cancer prior to starting the trial.

Inclusion: PSMA-N0M0 patients who have a documented history of High Risk localized adenocarcinoma of the prostate are eligible to participate if they meet the following eligibility criteria:; Participants capable of giving written informed consent; Male; Age ≥18 years; ECOG ≤2; Patient has histologically proven adenocarcinoma of prostate gland with an assigned Gleason score and Gleason Grade Group; ≥NCCN High-Risk localized disease as per standard imaging investigations including pelvic imaging (CT, MRI) and 99Tc bone scan. High Risk prostate cancer defined as any of the following: cT3-T4 disease OR PSA ≥20 ng/ml OR Gleason grade group 4 or 5; No documentation of regional nodal (N1) or metastatic (M1) prostate cancer on standard imaging (CT, MRI, or 99Tc bone scan); In the opinion of the treating oncologist, patient is fit to undergo radical external beam radiotherapy to the prostate; Patient commits to androgen suppression treatment as per standard of care. 10. Patient is willing to complete symptom and patient reported outcome questionnaires; Patients of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period and for a period of 6 months after the last dose of radiation therapy. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly. Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard; Male patients should agree to not donate sperm during the study and for 6 months after completion of radiation therapy.

Exclusion: Inability to complete the investigational imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.); Patients who have initiated therapy (ADT, systemic therapy, or radiation) for their prostate cancer prior to PSMA-PET imaging; History of prostatectomy or previous pelvic radiotherapy; Any additional medical condition, serious inter-current illness or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study performance, interpretation, or compliance with radiation; History of inflammatory bowel disease, anal stenosis, colorectal surgery, or repeated endoscopic examinations/interventions related to anorectal diseases; Previous malignancy within the last five years, except BCC or SCC skin or a malignancy treated curatively with no evidence of disease for ≥5 years; Bilateral hip prostheses will be ineligible for study.

ClinicalTrials.gov NCT07291557